Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease

Johan M. Lorenzen, Bernd Dietrich, Jan Fiedler, Virginija Jazbutyte, Felix Fleissner, Nicola Karpinski, Frank Weidemann, Christoph Wanner, Esther Asan, Massimiliano Caprio, Georg Ertl, Johann Bauersachs, Thomas Thum

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fabry disease is an X-chromosomal recessive deficiency of the lysosomal hydrolase alpha-galactosidase A (alpha-Gal). This results in an accumulation of globotriaosylceramide (GL-3) in a variety of cells often with subsequent functional impairment. Here, the impact of Fabry disease on the biology of circulating angiogenic cells (CACs) and the endothelial response to transient ischemia was investigated. Untreated patients with Fabry disease (n = 26), patients after initiation of alpha-Gal enzyme replacement therapy (ERT) (n = 16) and healthy controls (n = 26) were investigated. Endothelial function was assessed by the EndoPAT2000 device. CAC numbers were assessed by flow-cytometry, CAC function by a modified Boyden chamber assay. Fabry patients showed a pathologic endothelial response, which normalized after ERT. CACs were increased in number, but functionally impaired. Immunofluorescence and electron microscopy identified an accumulation of GL-3 in Fabry CACs. ERT attenuated CAC dysfunction and improved markers of oxidative stress response in Fabry patients via a reduction in GL-3 accumulation in vitro and in vivo. Silencing of alpha-Gal in healthy CACs impaired their migratory capacity underlining a key role of this enzyme for CAC function. CAC supernatant as well as CACs from Fabry patients impaired angiogenesis and migratory capacity of HUVECs providing a mechanistic link between CAC and endothelial dysfunction. CAC adhesion to TNF-α pre-stimulated HUVECs and tube formation was impaired by alpha-Gal knockdown. Fabry patients show a dysfunction of CAC and a pathologic endothelial response. ERT improves CAC and endothelial function and thus may attenuate development of cardiovascular disease in the long term in this patient population.

Original languageEnglish
Article number311
JournalBasic Research in Cardiology
Volume108
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Fabry Disease
Enzyme Replacement Therapy
Endothelial Cells
alpha-Galactosidase
Hydrolases
Fluorescence Microscopy
Cell Adhesion
Electron Microscopy
Flow Cytometry
Oxidative Stress
Cardiovascular Diseases
Ischemia
Cell Count

Keywords

  • Alpha-galactosidase
  • Cardiovascular complications
  • Circulating angiogenic cells
  • Endothelial function
  • Enzyme replacement therapy
  • Fabry disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Lorenzen, J. M., Dietrich, B., Fiedler, J., Jazbutyte, V., Fleissner, F., Karpinski, N., ... Thum, T. (2013). Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease. Basic Research in Cardiology, 108(1), [311]. https://doi.org/10.1007/s00395-012-0311-3

Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease. / Lorenzen, Johan M.; Dietrich, Bernd; Fiedler, Jan; Jazbutyte, Virginija; Fleissner, Felix; Karpinski, Nicola; Weidemann, Frank; Wanner, Christoph; Asan, Esther; Caprio, Massimiliano; Ertl, Georg; Bauersachs, Johann; Thum, Thomas.

In: Basic Research in Cardiology, Vol. 108, No. 1, 311, 2013.

Research output: Contribution to journalArticle

Lorenzen, JM, Dietrich, B, Fiedler, J, Jazbutyte, V, Fleissner, F, Karpinski, N, Weidemann, F, Wanner, C, Asan, E, Caprio, M, Ertl, G, Bauersachs, J & Thum, T 2013, 'Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease', Basic Research in Cardiology, vol. 108, no. 1, 311. https://doi.org/10.1007/s00395-012-0311-3
Lorenzen, Johan M. ; Dietrich, Bernd ; Fiedler, Jan ; Jazbutyte, Virginija ; Fleissner, Felix ; Karpinski, Nicola ; Weidemann, Frank ; Wanner, Christoph ; Asan, Esther ; Caprio, Massimiliano ; Ertl, Georg ; Bauersachs, Johann ; Thum, Thomas. / Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease. In: Basic Research in Cardiology. 2013 ; Vol. 108, No. 1.
@article{64f8898e230d46e289e246e26be7531f,
title = "Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease",
abstract = "Fabry disease is an X-chromosomal recessive deficiency of the lysosomal hydrolase alpha-galactosidase A (alpha-Gal). This results in an accumulation of globotriaosylceramide (GL-3) in a variety of cells often with subsequent functional impairment. Here, the impact of Fabry disease on the biology of circulating angiogenic cells (CACs) and the endothelial response to transient ischemia was investigated. Untreated patients with Fabry disease (n = 26), patients after initiation of alpha-Gal enzyme replacement therapy (ERT) (n = 16) and healthy controls (n = 26) were investigated. Endothelial function was assessed by the EndoPAT2000 device. CAC numbers were assessed by flow-cytometry, CAC function by a modified Boyden chamber assay. Fabry patients showed a pathologic endothelial response, which normalized after ERT. CACs were increased in number, but functionally impaired. Immunofluorescence and electron microscopy identified an accumulation of GL-3 in Fabry CACs. ERT attenuated CAC dysfunction and improved markers of oxidative stress response in Fabry patients via a reduction in GL-3 accumulation in vitro and in vivo. Silencing of alpha-Gal in healthy CACs impaired their migratory capacity underlining a key role of this enzyme for CAC function. CAC supernatant as well as CACs from Fabry patients impaired angiogenesis and migratory capacity of HUVECs providing a mechanistic link between CAC and endothelial dysfunction. CAC adhesion to TNF-α pre-stimulated HUVECs and tube formation was impaired by alpha-Gal knockdown. Fabry patients show a dysfunction of CAC and a pathologic endothelial response. ERT improves CAC and endothelial function and thus may attenuate development of cardiovascular disease in the long term in this patient population.",
keywords = "Alpha-galactosidase, Cardiovascular complications, Circulating angiogenic cells, Endothelial function, Enzyme replacement therapy, Fabry disease",
author = "Lorenzen, {Johan M.} and Bernd Dietrich and Jan Fiedler and Virginija Jazbutyte and Felix Fleissner and Nicola Karpinski and Frank Weidemann and Christoph Wanner and Esther Asan and Massimiliano Caprio and Georg Ertl and Johann Bauersachs and Thomas Thum",
year = "2013",
doi = "10.1007/s00395-012-0311-3",
language = "English",
volume = "108",
journal = "Basic Research in Cardiology",
issn = "0300-8428",
publisher = "D. Steinkopff-Verlag",
number = "1",

}

TY - JOUR

T1 - Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease

AU - Lorenzen, Johan M.

AU - Dietrich, Bernd

AU - Fiedler, Jan

AU - Jazbutyte, Virginija

AU - Fleissner, Felix

AU - Karpinski, Nicola

AU - Weidemann, Frank

AU - Wanner, Christoph

AU - Asan, Esther

AU - Caprio, Massimiliano

AU - Ertl, Georg

AU - Bauersachs, Johann

AU - Thum, Thomas

PY - 2013

Y1 - 2013

N2 - Fabry disease is an X-chromosomal recessive deficiency of the lysosomal hydrolase alpha-galactosidase A (alpha-Gal). This results in an accumulation of globotriaosylceramide (GL-3) in a variety of cells often with subsequent functional impairment. Here, the impact of Fabry disease on the biology of circulating angiogenic cells (CACs) and the endothelial response to transient ischemia was investigated. Untreated patients with Fabry disease (n = 26), patients after initiation of alpha-Gal enzyme replacement therapy (ERT) (n = 16) and healthy controls (n = 26) were investigated. Endothelial function was assessed by the EndoPAT2000 device. CAC numbers were assessed by flow-cytometry, CAC function by a modified Boyden chamber assay. Fabry patients showed a pathologic endothelial response, which normalized after ERT. CACs were increased in number, but functionally impaired. Immunofluorescence and electron microscopy identified an accumulation of GL-3 in Fabry CACs. ERT attenuated CAC dysfunction and improved markers of oxidative stress response in Fabry patients via a reduction in GL-3 accumulation in vitro and in vivo. Silencing of alpha-Gal in healthy CACs impaired their migratory capacity underlining a key role of this enzyme for CAC function. CAC supernatant as well as CACs from Fabry patients impaired angiogenesis and migratory capacity of HUVECs providing a mechanistic link between CAC and endothelial dysfunction. CAC adhesion to TNF-α pre-stimulated HUVECs and tube formation was impaired by alpha-Gal knockdown. Fabry patients show a dysfunction of CAC and a pathologic endothelial response. ERT improves CAC and endothelial function and thus may attenuate development of cardiovascular disease in the long term in this patient population.

AB - Fabry disease is an X-chromosomal recessive deficiency of the lysosomal hydrolase alpha-galactosidase A (alpha-Gal). This results in an accumulation of globotriaosylceramide (GL-3) in a variety of cells often with subsequent functional impairment. Here, the impact of Fabry disease on the biology of circulating angiogenic cells (CACs) and the endothelial response to transient ischemia was investigated. Untreated patients with Fabry disease (n = 26), patients after initiation of alpha-Gal enzyme replacement therapy (ERT) (n = 16) and healthy controls (n = 26) were investigated. Endothelial function was assessed by the EndoPAT2000 device. CAC numbers were assessed by flow-cytometry, CAC function by a modified Boyden chamber assay. Fabry patients showed a pathologic endothelial response, which normalized after ERT. CACs were increased in number, but functionally impaired. Immunofluorescence and electron microscopy identified an accumulation of GL-3 in Fabry CACs. ERT attenuated CAC dysfunction and improved markers of oxidative stress response in Fabry patients via a reduction in GL-3 accumulation in vitro and in vivo. Silencing of alpha-Gal in healthy CACs impaired their migratory capacity underlining a key role of this enzyme for CAC function. CAC supernatant as well as CACs from Fabry patients impaired angiogenesis and migratory capacity of HUVECs providing a mechanistic link between CAC and endothelial dysfunction. CAC adhesion to TNF-α pre-stimulated HUVECs and tube formation was impaired by alpha-Gal knockdown. Fabry patients show a dysfunction of CAC and a pathologic endothelial response. ERT improves CAC and endothelial function and thus may attenuate development of cardiovascular disease in the long term in this patient population.

KW - Alpha-galactosidase

KW - Cardiovascular complications

KW - Circulating angiogenic cells

KW - Endothelial function

KW - Enzyme replacement therapy

KW - Fabry disease

UR - http://www.scopus.com/inward/record.url?scp=84869868299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869868299&partnerID=8YFLogxK

U2 - 10.1007/s00395-012-0311-3

DO - 10.1007/s00395-012-0311-3

M3 - Article

VL - 108

JO - Basic Research in Cardiology

JF - Basic Research in Cardiology

SN - 0300-8428

IS - 1

M1 - 311

ER -